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Viruses are highly evolved and ubiquitous pathogens. 
Although infection with many viruses results in a mild, 
self-limited disease, other viruses can produce severe 
and frequently fatal infections. The respiratory tract is 
a major portal through which viruses enter to initiate 
infection. Whereas some viruses can initiate infection 
in the respiratory tract and then disseminate to other 
sites in the body, other viruses typically remain local-
ized to the respiratory tract, where they replicate and 
induce tissue injury (see Supplementary information S1 
(table)). Various defence mechanisms have evolved in 
the respiratory tract to prevent and control infection by 
viruses and other pathogens.
The respiratory tract can be divided anatomically 
into the upper respiratory tract (including the nose, 
mouth and pharynx) and the lower respiratory tract 
(which consists of the trachea, bronchi and lungs), with 
the lymphoid tissue of Waldeyer’s ring (including the 
pharyngeal and palatine tonsils) representing the line 
of demarcation. Because of the crucial role of the lower 
respiratory tract in respiration, we limit the focus of this 
Review to recent advances in our understanding of the 
host immune response to virus infection at this site.
Stromal cells (typically CD45– non-haematopoietic 
cells) and haematopoietic cells (CD45+ bone marrow-
derived cells) comprise the cellular network of the lower 
respiratory tract. Although all cell types presumably 
have important roles during respiratory virus infection, 
type I and type II alveolar epithelial cells and conducting 
airway epithelial cells are of particular importance 
among the CD45– stromal cells, as infection of these 
cells by viruses and the subsequent host immune 
response can compromise respiratory function and 
can result in acute respiratory distress syndrome (ARDS). 
Type I and type II alveolar epithelial cells are important 
cellular targets for infection by severe acute respiratory 
syndrome (SARS) coronavirus1,2 and certain type A 
influenza virus strains, most notably the highly patho-
genic avian H5N1 viruses3–5. Viruses can also target epi-
thelial cells of the conducting airways (Supplementary 
information S1 (table)).
The severe lung inflammation associated with res-
piratory infection by certain viruses poses a unique chal-
lenge to the immune system: not only must the virus 
be rapidly eliminated by the immune system, but tissue 
inflammation must also be controlled to prevent acute 
respiratory failure. Furthermore, during the recovery 
or resolution phase of infection, the immune system 
must help to orchestrate tissue repair to restore normal 
lung architecture and function and prevent permanent 
defects in respiratory function.
The contributions of physical and chemical barriers 
to infection and of the various innate immune mecha-
nisms and cell types that mediate host responses to virus 
infections have been recently reviewed6–9 and are not dis-
cussed in detail here (although they are summarized in 
Supplementary information S2 (box)). Likewise, the func-
tion of B cells in immunity to respiratory viruses has been 
reviewed elsewhere10. Here, we primarily focus on recent 
results regarding the induction of T cell responses to virus 
infection in the respiratory tract and the role of specific 
respiratory dendritic cell (DC) subsets and macrophages 
in controlling this process. In addition, we describe recent 
findings on the regulation of immunity, pulmonary 
inflammation and injury during virus infection. Finally, 
we briefly consider the potential link between respiratory 
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Abstract | Recent years have seen several advances in our understanding of immunity to virus 
infection of the lower respiratory tract, including to influenza virus infection. Here, we review 
the cellular targets of viruses and the features of the host immune response that are unique 
to the lungs. We describe the interplay between innate and adaptive immune cells in  
the induction, expression and control of antiviral immunity, and discuss the impact of the 
infected lung milieu on moulding the response of antiviral effector T cells. Recent findings 
on the mechanisms that underlie the increased frequency of severe pulmonary bacterial 
infections following respiratory virus infection are also discussed.
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Type I and type II alveolar 
epithelial cells
Type I alveolar epithelial cells 
(also known as squamous 
alveolar cells and type I 
pneumocytes) form the 
structure of the alveolar wall and 
are responsible for gas exchange 
in the alveoli. Type II alveolar 
epithelial cells (also known as 
great alveolar cells) continually 
secrete pulmonary surfactant 
to lower the surface tension of 
pulmonary fluids, thereby 
increasing gas exchange.
Acute respiratory distress 
syndrome
(ARDS). A severe inflammatory 
disease of the lung that is usually 
triggered by another pulmonary 
pathology. The uncontrolled 
inflammation leads to impaired 
gas exchange, alveolar flooding 
and/or collapse, and systemic 
inflammatory response 
syndrome.
virus infection and chronic respiratory diseases and dis-
cuss in more detail the recent findings relating to the effect 
of respiratory tract virus infection on the susceptibility to 
concurrent or subsequent bacterial infection (known as 
bacterial superinfection).
Respiratory APC activation and emigration
The lungs are bombarded by a plethora of innocuous 
inhaled antigens and presumably by commensal micro-
organisms. A unique challenge for lung-resident antigen- 
presenting cells (APCs) is to discriminate between invad-
ing pathogens and innocuous particles and to deliver only 
relevant microbial antigens to T cells. The mechanisms 
of this discrimination in the lungs are poorly under-
stood but ultimately result in the activation of respiratory 
DCs and their migration to draining lymph nodes.
Alveolar macrophages. If intracellular innate immune 
mechanisms in primary target cells (such as epithelial 
cells) fail to adequately control early virus replication, 
and replication proceeds, then released virions and the 
contents of dying or dead infected cells can be taken up 
by a variety of APCs9 (TABLE 1). The first respiratory tract 
CD45+ immune cell type to encounter viral antigens is the 
alveolar macrophage. Not only are alveolar macrophages 
superb phagocytes that are capable of rapidly eliminat-
ing large numbers of microorganisms from the lung, 
but they also have a crucial role in dampening immune 
responses at this site11. It is widely believed that alveolar 
macrophages are non-migratory and do not contribute to 
the induction of adaptive immune responses. However, 
recent evidence indicates that alveolar macrophages can 
migrate from the lung to the draining lymph nodes under 
homeostatic conditions and can serve as antigen carriers 
following bacterial infection12, although their contribu-
tion to the induction of adaptive immune responses in 
the draining lymph nodes is currently undefined.
Dendritic cells. DCs reside below the airway epithelial 
cells within the pulmonary interstitium, and they can 
extend processes between airway epithelial cells, making 
them strategically poised to sample airway particulates, 
such as viruses. Several phenotypically and functionally 
distinct subsets of respiratory DCs have been studied 
extensively in rodents13. These populations include 
two main resident mature (MHC class IIhiCD11chi) 
Table 1 | Cells with antigen-presenting functions in the lung during respiratory virus infection
Cell type Mechanism Effect or outcome Refs
CD103+ lung DCs MHC class I presentation and 
cross-presentation
Naive CD8+ T cell proliferation 14,17, 
37,38
MHC class II presentation Naive CD4+ T cell proliferation 14,37
CD11bhi lung DCs MHC class I presentation Naive CD8+ T cell proliferation 14,37
MHC class II presentation Naive CD4+ T cell proliferation 14,37
Cross-priming and expression 
of CD70
Expansion of effector CD8+ T cell populations 40
Chemokine production Numerous 22
Plasmacytoid DCs Unknown Suppression of excessive inflammation and 
promotion of virus clearance during RSV infection
87
Monocyte-derived 
DCs or macrophages
MHC class I presentation Naive CD8+ T cell proliferation and production of 
iNOS and TNF 
24
Production of IL-12 Development of T
H
1 cells 44
Expression of TRAIL and PPARγ Effector CD8+ T cell proliferation; promotion or 
healing of injury (depending on macrophage type)
24,25, 
54
CD11c+ lung DCs CD80 and CD86 co-stimulation Cytokine production by effector CD8+ T cells 49,69
Production of LTβ, CXCL12, 
CXCL13, CCL19 and CCL21
iBALT formation 120,121
Trans-presentation of IL-15 Effector T cell survival 63,74
Type II alveolar 
epithelial cells
MHC class II presentation T
Reg
 cell differentiation; effector CD4+ T cell 
activation
57,122
Airway epithelial cells Failure to provide co-stimulation Lack of pro-inflammatory cytokine production 49
Alveolar 
macrophages
Production of PGE2, IL-10 and 
TGFβ; expression of CD200R 
Promotion or inhibition of antigen-specific T cell 
stimulation 
123,124
NK cells or IKDCs MHC class I presentation Antigen presentation to CD8+ T cells 125
LAPCs MHC class II presentation Differentiation of T
H
2 cells 126
CCL, CC-chemokine ligand; CXCL, CXC-chemokine ligand; DC, dendritic cell; iBALT, inducible bronchus-associated lymphoid 
tissue; IKDC, IFN-producing killer DC; IL, interleukin; iNOS, inducible nitric oxide synthase; LAPC, late-activator 
antigen-presenting cell; LTβ, lymphotoxin-β; NK, natural killer; PGE2, prostaglandin E2; PPARγ, peroxisome proliferator-activated 
receptor-γ; RSV, respiratory syncytial virus; TGFβ, transforming growth factor-β; T
H
, T helper; TNF, tumour necrosis factor; TRAIL, 
TNF-related apoptosis-inducing ligand; T
Reg
, regulatory T.
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derived DC
Plasmacytoid DCs
(pDCs). A dendritic cell (DC) 
subtype defined by the 
expression of CD11c and  
B220 and the lack of CD8 and 
CD11b. pDCs are specialized  
to produce large amounts of 
type I interferons in response 
to viral infection, and they 
therefore have an important 
role in the immune response  
to viruses.
respiratory DC subsets, which are characterized as 
CD103+ and CD11bhiCD103– respiratory DCs and are 
crucial for the induction of adaptive immune responses, 
at least in mice14–17. CD103+ respiratory DCs localize at 
the mucosal surface, adjacent to the respiratory epithe-
lium, and surround adjoining vasculature. By contrast, 
the more abundant CD11bhi respiratory DC subset is 
found within the lung interstitium. CD103+ respiratory 
DCs express the mannose-binding C-type lectin langerin 
(also known as CLEC4K)16,18 and require expression of 
specific transcriptional factors (such as BATF3) for their 
normal development in the lung and at other mucosal 
surfaces19–21. Activated CD103+ respiratory DCs pro-
duce modest levels of pro-inflammatory mediators, 
whereas CD11bhi respiratory DCs are major chemokine 
producers in response to pulmonary inflammation22.
Monocyte-derived DCs, which are phenotypically 
immature (MHC class IIlowCD11clow), are more abun-
dant than the mature DC subsets and localize within 
the interstitium. They can take up particulates in the 
inflamed lung and migrate to the draining lymph nodes. 
However, they were found to be poor activators of 
naive T cells when analysed during experimental virus 
infections14. They may, however, serve as precursors for 
mature DCs23 (FIG. 1). Distinct from these conventional 
respiratory DCs are plasmacytoid DCs (pDCs). pDCs 
are recognized as major producers of type I interferons 
(IFNs) during infection, and can also transport antigens 
from the infected lung to the draining lymph nodes. 
However, the low-level expression of co-stimulatory 
ligands on pDCs renders them weak activators of 
naive T cells.
Figure 1 | Innate immunity to respiratory virus infection. Virus infection of respiratory epithelial cells is first detected 
by cytosolic and/or endosomal innate sensors in the infected epithelial cells (not shown). Recognition of the invading virus 
by these innate immune receptors leads to the production of pro-inflammatory cytokines such as interleukin-1β (IL-1β) 
and IL‑18, and chemokines such as CC‑chemokine ligand 2 (CCL2). These soluble mediators that are released by infected 
cells activate adjacent CD45– parenchymal cells, such as fibroblasts and epithelial cells, and neighbouring innate immune 
cells. Following activation, these cells convert latent transforming growth factor-β (TGFβ) to an active form, resulting in 
increased secretion of the chemokines CCL2 and CCL20 by parenchymal stromal cells and of cytokines such as IL-12 and 
tumour necrosis factor (TNF) by inflammatory cells. This enhanced production of chemokines and cytokines facilitates 
the maturation of tissue-resident CD103+ and CD11b+ dendritic cells (DCs) and the recruitment and maturation of 
monocyte-derived DCs. Antigen acquisition and activation of immature antigen-bearing respiratory DCs results in their 
mobilization and migration out of the infected lungs along chemokine gradients of CCL21 and sphingosine-1-phosphate 
(S1P) to the lymph nodes draining the infected lung. Once in the lymph nodes, these DCs participate in initiating adaptive 
immune responses to the respiratory virus (not shown).
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Integrin
A member of a group of 
proteins that regulate the 
attachment of cells to one 
another (cell–cell adhesion) 
and to the surrounding 
network of proteins and  
other molecules (cell–matrix 
adhesion). Integrins also 
transmit chemical signals that 
regulate cell growth and the 
activity of certain genes.
Sphingosine-1-phosphate
(S1P). A sphingolipid that is 
involved in signalling. In the 
immune system, S1P induces 
the egress of lymphocytes 
from lymphoid organs by 
binding to S1P receptors on 
the cells.
Cross-presentation
A mechanism that can initiate 
a CD8+ T cell response to an 
antigen that is not present 
within antigen-presenting cells 
(APCs). This exogenous antigen 
must be taken up by APCs  
and then re-routed to the  
MHC class I pathway of 
antigen presentation.
Efferocytosis
The phagocytic clearance of 
apoptotic cells before they 
undergo secondary necrosis. 
The process usually triggers an 
anti-inflammatory response.
Inflammatory DCs
Dendritic cells (DCs) that are 
not normally present in the 
steady state but develop as a 
result of inflammation or 
microbial stimuli. For example, 
one such subset is tumour 
necrosis factor- and inducible 
nitric oxide synthase-producing 
DCs (TIP DCs). Inflammatory 
monocytes can also give rise  
to inflammatory DCs.
Macrophages. In addition to alveolar macrophages, 
CD11b+ (CD11c–) tissue-resident macrophages — which 
originate from circulating CC-chemokine receptor 2 
(CCR2)+ monocytic subsets in the blood — are found 
within the non-inflamed pulmonary interstitium9,24,25. 
These cells have the capacity to transport antigens from 
the lungs to the draining lymph nodes during virus 
infection14, although their contribution to the induction 
of adaptive immune responses is unclear. The number of 
these macrophages can increase dramatically in response 
to virus infection, and they may serve as APCs for acti-
vated effector T cells in the infected lungs24,25 (see below). 
Recent evidence suggests that the increase in the number 
of macrophages during infection may result both from 
an influx of blood monocyte precursors and from local 
cell proliferation26.
Migration of respiratory DCs. Respiratory virus infec-
tion (and other inflammatory stimuli) triggers antigen 
uptake by and activation of most types of respiratory 
DC, resulting in their mobilization and migration out 
of the infected lungs9,27. Although this process is not 
fully understood, multiple mediators — including 
chemokines such as CC-chemokine ligand 2 (CCL2), 
CCL5, CCL20 and CCL21 — probably work in concert 
to orchestrate respiratory DC activation and mobiliza-
tion. These chemokines are produced by respiratory 
epithelial cells and vascular and lymphatic endothelial 
cells, and then engage their corresponding receptors on 
respiratory DCs28,29. Additional pro-inflammatory medi-
ators (such as interleukin-1β (IL-1β) and IL-18) that are 
released by infected epithelial cells can activate adjacent 
CD45– parenchymal cells, such as fibroblasts28. This may 
increase the expression of αVβ8 integrin on the fibroblasts 
and subsequent integrin-dependent activation of trans-
forming growth factor-β (TGFβ), resulting in increased 
secretion of the TGFβ-dependent chemokines CCL2 and 
CCL20 (REF. 28). Similarly, Toll-like receptor 4 (TLR4) 
signalling in epithelial cells in response to viral pro-
teins upregulates CCL2 and CCL20 expression29, which 
may facilitate the activation and mobilization of DCs 
within the lung, as well as the recruitment of monocyte 
progenitors into the lung from the circulation (FIG. 1).
The infection-induced crosstalk between CD45– 
lung parenchymal cells and mature resident DCs in 
the inflamed lung leads to the upregulation on the DCs 
of several chemotactic receptors, most notably CCR7 
and sphingosine-1-phosphate receptors. These receptors 
are crucial for transendothelial migration of activated 
respiratory DCs and their egress to the draining lymph 
nodes14,15,30,31. Unlike CD103+ and CD11bhi respiratory 
DCs, other potential APCs — such as alveolar macro-
phages, pDCs and monocyte-derived DCs — use as yet 
unidentified pathways that are independent of CCR7 to 
enter the draining lymph nodes. Activated respiratory 
DCs also upregulate their expression of co-stimulatory 
and adhesion molecules (such as CD40, CD80, CD86 
and ICAM1) and of antigen-presenting molecules, and 
this renders the migrating respiratory DCs competent 
to serve as potent APCs for the activation of naive 
virus-specific T cells in the draining lymph nodes.
T cell activation and differentiation
The migration of respiratory DCs bearing viral anti-
gens to the draining lymph nodes serves to concen-
trate viral antigens at a site where extremely rare 
virus-specific adaptive immune cells, such as naive32,33 
and memory antiviral T cells34,35, can encounter their 
cognate antigens. Although the transfer of viral anti-
gens from migrant respiratory DCs (and macro-
phages) to lymph node-resident CD8α+ DCs has 
been documented in a respiratory virus infection36, 
several lines of evidence suggest that it is the antigen-
bearing migratory DCs that most efficiently present 
viral antigens to naive CD4+ and CD8+ T cells during 
respiratory virus infections14,17,37–41 (TABLE 1). However, 
the relative contributions of migratory respiratory DCs 
and lymph node-resident CD8α+ DCs to the activa-
tion of naive T cells during respiratory virus infection 
remain to be fully explored and are probably pathogen 
dependent.
Migrant CD103+ respiratory DCs reach maximum 
numbers in the draining lymph nodes early (2–4 days) 
following respiratory virus infection and serve as 
the most potent APCs for naive virus-specific CD8+ 
T cells early in the response to an active infection14,41. 
Furthermore, CD103+ respiratory DCs can efficiently 
cross-present antigens (such as products of infected 
cells) that were initially taken up in the lungs, possibly 
via efferocytosis42. The limited data currently available 
do not allow a definitive determination of whether 
infected CD103+ respiratory DCs are more potent 
APCs for naive CD8+ T cells than CD103+ respiratory 
DCs that cross-present acquired viral antigens14,41. 
Recently, the superiority of CD103+ respiratory DCs 
over CD11bhi respiratory DCs in supporting antiviral 
CD8+ T cell activation during influenza virus infection 
was linked with their enhanced capacity to process 
and load viral antigens onto MHC class I molecules 
for presentation to CD8+ T cells43.
CD11bhi respiratory DCs reach peak numbers in the 
draining lymph nodes at later time points (5–7 days) 
following influenza virus infection14,41 and may act to 
expand the pool size of previously activated effector 
CD8+ T cells in the draining lymph nodes through 
engagement of the co-stimulatory receptor CD27 
(REF. 40). The speed and magnitude of migratory DC 
accumulation in the lymph nodes are probably regu-
lated by virus-intrinsic factors, such as replication 
potential, target cell type and cytotoxic effects, as well 
as by host-intrinsic factors, such as underlying genetic 
susceptibility. 
Both major migratory respiratory DC subsets 
also efficiently activate naive virus-specific CD4+ 
T cells14. Furthermore, the influx of inflammatory DCs 
into the draining lymph nodes from the circulation 
has an important role in activating potent T helper 1 
(TH1) cell responses to respiratory virus infection
44. 
Following the resolution of acute infection, CD103+ 
and CD11b+ respiratory DCs continue to ferry and 
present residual antigens to memory T cells34,35, and 
as a consequence they influence the trafficking and 
recall responses of antiviral memory T cells45–47.
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T cell-mediated antiviral responses
Following their encounter with APCs in the draining 
lymph nodes, naive (and memory) virus-specific T cells 
undergo a stepwise process of activation, proliferation 
and differentiation to become effector T cells that can 
migrate to the site of infection and mediate antiviral 
immune responses.
Effector mechanisms. The effector mechanisms used by 
antiviral T cells can be categorized into three groups. First, 
there are T cell-associated lytic mechanisms that pro-
mote the lysis of infected cells following the exocytosis of 
perforin- and granzyme-containing granules. Second, 
T cells can induce tumour necrosis factor receptor 
(TNFR) family-dependent apoptosis of infected cells by 
expressing CD95 ligand (also known as FAS ligand) or 
TNF-related apoptosis-inducing ligand (TRAIL). Third, 
T cells can produce pro-inflammatory mediators (and 
regulatory mediators (see below)) in response to encoun-
ter with virus-infected cells. Much of our current know-
ledge of these processes and their role in virus clearance 
has come from studies on the host adaptive immune 
T cell response to infection by a limited number of 
respiratory viruses, most notably influenza virus.
Several studies suggest a crucial role for the cytol-
ytic functions of CD8+ effector T cells in influenza virus 
infection. These functions trigger the direct lysis of 
virus-infected cells and require T cell receptor-mediated 
recognition of processed viral antigens on the infected 
target cell48–50. With certain notable exceptions51–53, the 
release of particular pro-inflammatory mediators (such 
as IFNγ) by CD8+ T cells has only a modest impact on 
virus clearance and recovery.
There is also recent evidence from the influenza virus 
model that virus-infected respiratory tract cells (specifi-
cally infected alveolar epithelial cells) may be eliminated 
during the host response through the action of activated 
lytic macrophages that are capable of triggering the apop-
tosis of virus-infected cells through a TRAIL-dependent 
mechanism54. Accordingly, activated inflammatory 
mono nuclear cells (rather than effector CD8+ T cells) that 
express TRAIL and are recruited into the virus-infected 
lungs could engage alveolar epithelial cells, which upreg-
ulate TRAIL receptor early in response to infection, and 
trigger alveolar epithelial cell apoptosis. The contribution 
of this mechanism to the control of virus replication and 
to the development of alveolar damage in the infected 
respiratory tract awaits further evaluation.
Effector CD4+ T cells have been demonstrated to 
exhibit cytotoxic activity in vitro, but the contribution of 
CD4+ T cell cytotoxicity to virus clearance in vivo in the 
lungs is modest55,56. This cytotoxicity is restricted to viral 
antigen-bearing cells that express MHC class II molecules; 
such cells include CD45+ inflammatory mono nuclear 
phagocytic cells and a few CD45– lung parenchymal cell 
types that constitutively (or inducibly) express MHC 
class II molecules (such as type II alveolar epithelial cells)57 
(TABLE 1). Results from experimental infection studies 
suggest that the primary role of anti viral CD4+ T cells is 
to support the activation and differentiation of B cells, 
which leads to antibody production58,59.
Modulating effector T cell responses in situ. The clas-
sical view of antiviral effector T cell generation posits 
that the proliferative expansion necessary for the differ-
entiation of activated naive antiviral T cells into effector 
T cells occurs primarily, if not exclusively, in the draining 
lymph nodes. The first hint that this earlier view may 
be incomplete in the case of respiratory virus infection 
came from studies demonstrating that activated effector 
T cells can undergo extensive proliferation in the respira-
tory tract60,61. More recent studies indicate a requirement 
for effector T cells in the infected lungs to interact with 
CD45+ inflammatory mononuclear phagocytes, which 
produce cytokines (such as IL-15, which they trans-
present) and/or express co-stimulatory molecules (such 
as CD70) to support the proliferation and sustain the 
viability of the effector T cells62–64.
In addition, a recent study demonstrated that virus-
specific CD8+ effector T cells can produce the regulatory 
cytokine IL-10 in response to antigenic stimulation but do 
so only following their migration into the virus-infected 
lungs65. It is noteworthy that a burst of T cell-derived IL-10 
production was shown to occur at the time of the initial 
influx of effector T cells into the lungs. This burst co incides 
with the peak of production of pro-inflammatory 
mediators such as IFNγ by the CD8+ effector T cells 
and with the onset of virus clearance65. IL-10-producing 
effector CD8+ T cells have been shown to simultaneously 
produce the pro-inflammatory cytokine IFNγ, and the 
production of both of these cytokines by CD8+ T cells 
decreases with virus clearance65. It remains to be deter-
mined whether this transition from an effector T cell 
capable of producing pro-inflammatory cytokines in the 
draining lymph nodes to an effector T cell that can pro-
duce both pro-inflammatory and regulatory cytokines 
after entering the virus-infected lungs represents a change 
in the activation state or in the differentiation state of 
the activated T cell. However, an examination of IL-10 
production by CD8+ effector T cells in vivo in infected 
lungs66 revealed that the production of this regulatory 
cytokine required exposure of the T cells in the infected 
lungs to IL-2 derived from antiviral CD4+ effector T cells 
and IL-27 produced by inflammatory mononuclear cells 
and neutrophils. These and other observations67 favour 
the view that the exposure of CD8+ effector T cells to 
pro-inflammatory (IL-27) and survival (IL-2) stimuli 
in the infected lungs enhances T cell activation, thereby 
facilitating Il10 gene expression.
An early in vitro analysis of the regulation of T cell 
effector activity suggested that there was an expressional 
hierarchy in T cell effector activities that was dependent 
on the strength of the activating stimulus68. According to 
this analysis, CD8+ T cell cytotoxic activity had the least 
stringent requirement for co-stimulatory and cytokine 
signals, followed by T cell proliferation, with pro- 
inflammatory cytokine production requiring the strong-
est co-stimulatory signals. Very recently, evidence has 
emerged from an in vivo analysis of T cell responses 
to respiratory virus infection to support this concept49. 
In this study, effector CD8+ T cell activation by influ-
enza virus-derived antigens that were presented by 
infected CD45– respiratory epithelial cells resulted in 
R E V I E W S
NATURE REVIEWS | IMMUNOLOGY  VOLUME 12 | APRIL 2012 | 299
© 2012 Macmillan Publishers Limited. All rights reserved
‘Effector’ TReg cell
A regulatory T (TReg) cell  
that expresses particular 
transcription factors, such  
as T-bet, and follows a 
differentiation pathway to 
acquire a phenotype or 
function for efficiently 
controlling a specific subset  
of effector T cells, such as  
TH1 cells.
Alternatively activated 
macrophages
(Also known as M2 
macrophages). Macrophages 
that are stimulated by IL-4 or 
IL-13 and that express 
arginase 1, the mannose 
receptor CD206 and IL-4 
receptor-α. There may be 
pathogen-associated 
molecular patterns expressed 
by helminths that can also 
drive the alternative activation 
of macrophages.
T cell-mediated killing of the infected epithelial cells 
without the release of pro-inflammatory cytokines. By 
contrast, effector CD8+ T cell activation by viral antigens 
that were presented by interstitial CD45+ inflammatory 
cells (primarily LY6ChiCD11c+ inflammatory mono-
nuclear phagocytes) induced cell-mediated cytotoxicity 
and pro-inflammatory cytokine production by the effec-
tor CD8+ T cells. The mechanism (or mechanisms) that 
account for this difference in the T cell response to APC 
or target cell recognition remains to be fully elucidated.
However, one crucial difference between the recog-
nition of CD45+ APCs and that of CD45– target cells by 
effector T cells is the expression of co-stimulatory ligands 
by APCs but not by target cells49,69. Indeed, blockade of 
the co-stimulatory molecules CD80 and CD86 in vitro or 
in vivo suppresses the production of pro-inflammatory 
cytokines by effector CD8+ T cells without affecting their 
cytotoxic activity in vitro or virus clearance in vivo49. 
Thus, the engagement of co-stimulatory receptors on 
effector CD8+ T cells by APCs would provide the addi-
tional signal strength necessary for the production of 
pro-inflammatory cytokines by the T cells. Several reports 
have evaluated the contribution of specific co-stimulatory 
receptor–ligand interactions in regulating the host adap-
tive immune response and the outcome of respiratory 
virus infection70–73. However, in most instances no spe-
cific distinction was made between the contribution of 
these co-stimulatory receptor–ligand interactions during 
the induction phase of the response in the draining lymph 
nodes and during the effector phase in the infected lungs.
The above results may have important implications 
for therapeutic intervention in respiratory tract infections 
with viruses (such as influenza virus) in which produc-
tive infection (that is production of infectious virions) 
is restricted to CD45– respiratory epithelial cells. More 
generally, these observations add to the emerging picture 
that, after entering the infected lungs, effector T cells are 
altered or moulded by the inflammatory milieu encoun-
tered in situ. Such alterations could include changes in 
activation state (such as increased avidity of the T cell 
receptor for its target peptide–MHC complex on APCs), 
in effector activity (such as the types and/or amounts of 
mediators produced) and in viability, and possibly the 
differentiation of certain effector T cells into memory 
T cells49,63,69,71,74.
Acute control of pulmonary inflammation
Multiple cell types express immunosuppressive mol-
ecules75 to maintain pulmonary homeostasis. This sup-
pressive state is disrupted by the action of innate and 
adaptive immune cells responding to infection. Their 
responses facilitate virus clearance but also can produce 
excessive pulmonary inflammation and tissue damage 
(reviewed in REF. 76) (FIG. 2).
Forkhead box  P3 (FOXP3)+ regulatory  T (TReg) 
cells have an important role in maintaining immune 
homeostasis by suppressing inflammation in naive 
hosts. However, it has recently been demonstrated that 
activated TReg cells can acquire unique phenotypes that 
enhance their ability to control exaggerated inflamma-
tion77,78. Following respiratory virus infection, TReg cells 
in the lungs have been shown to express ‘effector’ TReg cell 
markers. For instance, the expression of the TH1 cell-
associated transcription factor T-bet is upregulated in 
lung TReg cells during influenza virus infection
65 and is 
associated with enhanced TReg cell-mediated suppres-
sion of excessive TH1-type inflammatory responses
79. 
Similarly, BLIMP1 (B lymphocyte-induced maturation 
protein 1; also known as PRDM1), which is required for 
the terminal differentiation of effector T cells, is neces-
sary for the enhanced production of IL-10 by TReg cells 
during influenza virus infection65,67. The depletion of 
TReg cells leads to excessive pulmonary inflammation 
and injury during respiratory syncytial virus (RSV) 
infection80–82. Furthermore, the adoptive transfer of TReg 
cells into recombination-activating gene (RAG)-deficient 
mice (which lack B and T cells) controls the otherwise 
lethal inflammation mediated by innate immune cells 
during influenza virus infection83. These data suggest 
that TReg cells may be crucial for controlling acute host 
inflammation and for restoring lung homeostasis follow-
ing respiratory virus infection, although the mechanisms 
underlying these functions are poorly understood.
In addition to effector TReg cells, conventional effec-
tor CD4+ and CD8+ T cells have recently been shown 
to exert a ‘regulatory’ function through the production 
of high levels of IL-10 during influenza virus, RSV or 
simian virus 5 infection65,84,85. Blocking T cell-derived 
IL-10 results in excessive pulmonary inflammation 
characterized by increased accumulation of CD45+ 
inflammatory cells and enhanced production of pro-
inflammatory mediators during influenza virus or RSV 
infection65,85,86. As mentioned above, the production of 
IL-10 by effector T cells is primarily restricted to the 
site of infection rather than the site of T cell priming, 
suggesting that the local environment of the infected 
lungs can instruct the function of effector T cells65,84.
Various innate immune cell types may also act to 
suppress excessive inflammation arising from antiviral 
immune responses (TABLE 1). pDCs have a crucial role in 
restricting excessive T cell-mediated inflammation dur-
ing experimental RSV infection through an unknown 
mechanism87. In addition, neutrophils can facilitate 
viral clearance and dampen inflammation88, and lung 
epithelial cells can inhibit the over-exuberant inflamma-
tory activities of macrophages through the expression of 
the inhibitory molecule CD200 during influenza virus 
infection11. Furthermore, classically activated phagocytes 
(such as inflammatory DCs and macrophages) can be 
significant contributors to disease pathogenesis during 
influenza virus infection24,25,54, whereas alternatively 
activated macrophages have a regulatory function in RSV 
infection, dampening virus-induced inflammation driven 
by innate immune cells89. Of note, activation of the nuclear 
receptor peroxisome proliferator-activated receptor-γ 
(PPARγ) — a transcription factor that controls the dif-
ferentiation of monocyte precursors into alternatively 
activated macrophages90 — suppresses lethal inflamma-
tion during influenza virus infection25. Therefore, the 
differentiation state of the responding immune cell may 
have a crucial role in the resolution of inflammation and 
the outcome of virus infection (TABLE 1).
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Figure 2 | Regulatory mechanisms in the lung during respiratory virus infection. 
Molecules derived from both innate and adaptive immune cells contribute to the 
regulation of excessive pulmonary inflammation during acute respiratory virus 
infection. CD4+ T helper 1 (T
H
1) cells and type 1 CD8+ cytotoxic T cells (T
C
1 cells) 
express the transcription factors T‑bet and BLIMP1 (B lymphocyte‑induced maturation 
protein 1) and produce high levels of the regulatory cytokine interleukin‑10 (IL‑10),  
in addition to effector cytokines and cytolytic molecules, during respiratory virus 
infection. Regulatory T (T
Reg
) cells in the lungs also express the ‘effector’ transcription 
factors T-bet and BLIMP1, produce various immunoregulatory cytokines (including 
IL-10 and transforming growth factor-β1 (TGFβ1)) and express the inhibitory 
receptor cytotoxic T‑lymphocyte antigen 4 (CTLA4). Lung epithelial cells express 
CD200 and are required for the control of exuberant activation of classically 
activated macrophages. By contrast, alternatively activated macrophages  
contribute to the control of excessive pulmonary inflammation. Plasmacytoid 
dendritic cells (pDCs) also contribute to the suppression of excessive T cell‑mediated 
inflammation through an unidentified mechanism. iNOS, inducible nitric oxide 
synthase; PPARγ, peroxisome proliferator-activated receptor-γ; TNF, tumour necrosis 
factor; TRAIL, TNF-related apoptosis-inducing ligand.
The immunosuppressive cytokine TGFβ1 is consti-
tutively expressed by many lung cell types, most nota-
bly epithelial cells, which express the integrins required 
to convert latent TGFβ1 into the active form and can 
therefore maintain immune homeostasis in the normal 
lung75. Administration of TGFβ1 to mice during influ-
enza virus or RSV infection impairs virus clearance but 
suppresses the associated lung inflammation91, whereas 
inhibition of TGFβ1 during influenza virus infection 
results in lethal tissue injury92. Interestingly, whereas 
the neuraminidase protein from certain influenza virus 
strains can process latent TGFβ1 into its active form 
and thereby potentially dampen pulmonary inflamma-
tion during infection, neuraminidase from the highly 
pathogenic H5N1 influenza virus cannot process 
TGFβ1 (REF. 92). Therefore the ability (or inability) of 
a virus to activate or inhibit host immunoregulatory 
mechanisms (such as TGFβ1 activation) may con-
tribute to viral pathogenesis. So, there appear to be 
multiple layers of immunoregulation during acute res-
piratory virus infection at both the cellular level (such 
as TReg cells and other cells) and the molecular level 
(such as IL-10, CD200 and TGFβ1) (FIG. 2).
Bacterial superinfection following virus clearance
Epidemiological evidence has clearly suggested that 
respiratory virus infection, in particular type A influ-
enza virus infection, increases the incidence and sever-
ity of secondary bacterial infections in the respiratory 
tract93. Histological analyses of infected lung tissue 
indicates that bacterial superinfection resulting in 
secondary bacterial pneumonia was the predominant 
cause of death during the 1918 type A influenza virus 
pandemic and the more recent H1N1 pandemic94,95. 
In a mouse model of bacterial superinfection, type A 
influenza virus infection increases the susceptibil-
ity of mice to various bacterial infections, including 
respiratory challenge with Streptococcus pneumoniae, 
Staphylococcus aureus or Haemophilus influenzae and 
systemic Listeria monocytogenes infection96,97. Increased 
susceptibility to bacterial superinfection typically starts 
as early as day 3 and continues until at least 2 weeks 
post type A influenza virus infection. The prevailing 
opinion to explain this susceptibility to superinfec-
tion has, for many years, been that type A influenza 
virus infection damages epithelial cells and degrades 
the barrier function of the epithelium, thereby facili-
tating bacterial colonization of the respiratory tract93. 
However, evidence has emerged over the past decade 
suggesting that type A influenza virus infection also 
alters the function of innate and adaptive immune cells, 
resulting in a failure to effectively control bacterial 
replication (FIG. 3).
Among the various immune cell types, lung-resident 
alveolar macrophages are the first line of defence against 
bacteria in the respiratory tract, as they are capable of 
both limiting bacterial outgrowth and orchestrating the 
recruitment and activation of other immune cells to 
restrict bacterial growth. Type A influenza virus infec-
tion reduces the numbers of alveolar macrophages 
by promoting their apoptosis and also suppresses the 
function of these cells through direct mechanisms 
(such as infection of the macrophages) and indirect 
mechanisms (via host factors induced by the infec-
tion)98,99. Alveolar macrophages from lungs infected 
with type A influenza virus show increased expression 
of the CD200 receptor (CD200R), ligation of which 
suppresses alveolar macrophage activation in response 
to secondary bacterial challenge100. Furthermore, 
alveolar macrophages from virus-infected lungs 
exhibit decreased expression of the scavenger recep-
tor MARCO (macrophage receptor with collagenous 
structure) and a diminished ability to ingest bacteria99. 
They also produce only low levels of the cytokines and 
chemokines required for orchestrating the responses 
of other cell types against bacterial infection, such as 
neutro phil recruitment and activation98. The dimin-
ished chemokine production by alveolar macrophages 
from virus-infected lungs is associated with decreased 
translocation of nuclear factor-κB (NF-κB) to the 
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Figure 3 | Respiratory virus infection and susceptibility to secondary bacterial 
infection. Multiple distinct mechanisms have been postulated to account for the 
increased susceptibility to bacterial superinfection and bacterial pneumonia following 
infection with respiratory viruses such as type A influenza viruses. Influenza virus infection 
induces the production of type I interferons (IFNs), which inhibit the recruitment of 
circulating neutrophils and macrophages to the lung following bacterial challenge.  
Type I IFNs also inhibit the differentiation of antibacterial T helper 17 (T
H
17) cells from 
naive T cells (T
H
0 cells) or other T
H
 cell types (such as T
H
1 and T
H
2 cells)110 and thereby 
potentiate host susceptibility to secondary bacterial infection. IFNγ production by 
influenza virus‑specific effector T cells decreases the expression of macrophage receptor 
with collagenous structure (MARCO) by alveolar macrophages and inhibits the ingestion 
of bacteria by these cells. Moreover, interleukin-10 (IL-10) production by influenza 
virus‑specific effector T cells may inhibit the ability of innate immune cells, in particular 
macrophages, to kill bacteria. Finally, the direct interaction and/or infection of innate 
immune cells — such as macrophages, neutrophils and natural killer (NK) cells — with 
influenza virus suppresses the ability of these cells to take up and kill bacteria.
nucleus of alveolar macrophages as a result of as yet 
unidentified mechanisms98. The desensitization of 
alveolar macrophages can last for several months after 
influenza virus infection. Therefore, given the impor-
tant role of alveolar macrophages in the initial control 
of bacterial infection, these data suggest that individuals 
who have recovered from severe influenza virus infec-
tion may have compromised immunity to subsequent 
bacterial infections for extended time periods.
In addition to suppressing alveolar macrophages, 
influenza virus infection inhibits the recruitment of cir-
culating monocytes and macrophages during responses 
to bacterial challenge through type I IFN-dependent 
mechanisms101. Neutrophils have a crucial role in clear-
ing pulmonary bacterial infection, but those isolated 
from influenza virus-infected lungs exhibit impaired 
responses to bacterial challenge102. Indeed, influenza 
virus infection of (or binding to) neutrophils in vitro 
results in a direct inhibition of neutrophil chemotaxis 
and superoxide production103. In vivo, influenza virus 
can directly infect neutrophils in the lung and, thus, 
may directly suppress the function of neutrophils dur-
ing secondary bacterial challenge104. Furthermore, 
type I IFN production induced during primary influ-
enza virus infection can directly inhibit neutrophil 
infiltration into the lung and/or increase the apoptosis 
of neutrophils105.
Natural killer (NK) cells, via their release of anti-
bacterial factors, can also serve as important effector 
cells during certain bacterial infections106. However, 
NK cells isolated from influenza virus-infected lungs 
show decreased production of the antibacterial effector 
cytokine TNF106, although the mechanisms underlying 
this defect in NK cell function during influenza virus 
infection remain elusive. NK cells are reported to be 
susceptible to infection by influenza virus, and infected 
NK cells have various defects in effector activities such as 
cytotoxicity and cytokine and chemokine production107.
Influenza virus infection induces highly polarized 
TH1-type immune responses characterized by the pro-
duction of IFNγ. Of note, neutralization of IFNγ during 
influenza virus infection restores MARCO expression 
by macrophages, increases bacterial ingestion and kill-
ing by macrophages and enhances host resistance to 
secondary bacterial infection99. Highly polarized CD4+ 
TH1 cells and type 1 CD8
+ cytotoxic T cells are also a 
major source of the anti-inflammatory cytokine IL-10 
during influenza virus infection65,108. IL-10 has been 
implicated in the susceptibility to secondary bacterial 
infections following influenza virus infection. In one 
study, the blockade of IL-10 enhanced the clearance of 
a secondary infection with S. pneumoniae109. However, 
the role of IL-10 during secondary bacterial infection 
remains controversial, as two recent reports using 
IL-10-deficient mice found a minimal role for IL-10 
in regulating host susceptibility to secondary bacte-
rial challenge99,105. TH17 cell responses are also crucial 
for host resistance to challenges with certain bacteria, 
including S. pneumoniae and S. aureus110, and influ-
enza virus-induced production of type I IFNs has been 
shown to suppress the subsequent development of TH17 
cells in response to bacterial superinfection110.
In summary, emerging evidence suggests that one or 
more of the regulatory mechanisms (for example, the 
expression of CD200R, IL-10 and/or TGFβ1) that are 
used by innate and adaptive immune cells to suppress 
excess inflammation during acute respiratory virus infec-
tions may facilitate bacterial colonization by diminish-
ing the recruitment and function of phagocytes and the 
subsequent destruction of bacterial pathogens (FIG. 3). If 
immune mechanisms aimed at controlling virus replica-
tion and/or excessive inflammation in the virus-infected 
lungs predispose the individual to bacterial super-
infection, then therapeutic strategies to prevent bacte-
rial superinfection in the lungs must balance the need 
to prevent virus replication and excessive inflammation 
during virus clearance with the need to optimize the 
antibacterial functions of innate immune phagocytes.
Lower respiratory tract virus infections can, if severe, 
also alter lung function for an extended period after 
virus clearance and potentially predispose to, or at least 
exacerbate, chronic pulmonary inflammatory diseases 
such as asthma and chronic obstructive pulmonary 
disease (BOX 1).
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Innate lymphoid cells
(ILCs; also known as natural 
helper cells and nuocytes). 
Cells that combine innate and 
adaptive immune functions 
and are part of the first line of 
defence against mucosal 
infections. ILCs are distinguished 
from adaptive lymphocytes  
by their independence from  
recombination-activating 
genes and the resulting 
absence of specific antigen 
receptors. They produce large 
quantities of type 2 cytokines 
such as IL-5 and IL-13.
Fibrocytes
Mature fibroblasts that no 
longer produce fibres or 
intercellular substance in 
connective tissue. Fibroblasts 
are large, flat cells that form 
the collagenous and elastic 
fibres and intercellular 
substance of loose connective 
tissue.
Conclusions
The recent advances in the identification and charac-
terization of distinct subsets of DCs within the respira-
tory tract, along with the elucidation of their functions 
as APCs before and during virus infection, offer the 
promise of developing newer and more effective vacci-
nation strategies against viral and other respiratory tract 
pathogens. The emerging evidence that the spectrum of 
effector activity exhibited by antiviral CD8+ T cells may 
differ depending on the level of co-stimulation that they 
receive raises the possibility that in the case of respira-
tory viruses, for which replication is restricted to res-
piratory epithelium, excessive inflammation associated 
with severe infection can be controlled by blocking co-
stimulatory signals, without altering immune-mediated 
virus clearance.
More generally, recent evidence strongly suggests 
that the activation state and function of effector T cells 
in virus-infected lungs are sculpted by the local milieu 
generated by the resident and infiltrating inflammatory 
cells and the factors that they produce in response to 
virus infection. This additional moulding of the immune 
response at the site of infection will have an impact on 
the process of virus clearance and an equally important 
effect on the regulation of acute inflammation, and 
possibly immunological memory.
Resolution of respiratory virus infection requires 
not only the elimination of the virus but also the repair 
and regeneration of normal lung structures and, most 
importantly, the restoration of normal pulmonary func-
tion. Although at present the resolution response is only 
poorly understood and appreciated, the cells and mol-
ecules of the innate and adaptive immune system that 
respond to virus infection in the lower respiratory tract 
will almost certainly be shown to contribute. Whether 
and how these cells and molecules regulate processes 
such as epithelial cell to mesenchymal cell transitions, 
as well as the transformation of fibroblasts and fibro-
cytes into myofibroblasts, will become an area of intense 
research, as dysregulation of these processes in response 
to lung inflammation is associated with progressive 
pulmonary injury and lung fibrosis.
Box 1 | Pulmonary diseases as sequelae of respiratory virus infection
Interleukin‑13 (IL‑13) is a crucial regulator of the development of chronic airway diseases, including asthma and  
chronic obstructive pulmonary disease (COPD)111,112. It has also been shown to have an essential role in various models 
of virus‑induced airway diseases, although the specific cellular sources of IL‑13 differ among the various models. 
Classically, T helper 2 (T
H
2) cells are thought to be responsible for the development of asthma‑like diseases following 
infection by a respiratory virus, such as respiratory syncytial virus (RSV)113 or Sendai virus114. In a model of Sendai 
virus‑induced chronic disease, IL‑13 production by invariant natural killer T (iNKT) cells and alternatively activated 
macrophages induced persistent mucus production and airway inflammation115. In influenza virus‑induced airway 
hyperreactivity, IL‑13 was primarily produced by the recently described type 2 innate lymphoid cells116,117 (ILC2 cells; 
also known as nuocytes and natural helper cells118) in response to IL‑33 and was responsible for the induction of airway 
hyperreactivity during the acute phase of influenza virus infection. Interestingly, ILC2 cells also have an important role 
in the repair of the damaged lung during influenza virus infection through a mechanism dependent on amphiregulin  
(an epidermal growth factor family member)119. This suggests that the development of chronic diseases following acute 
respiratory virus infection may be an aberrant by‑product of the lung repair process.
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